Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.

El-Nemr A, Bhide M, Khalifa Y, Al-Mizyen E, Gillott C, Lower AM, Al-Shawaf T, Grudzinskas JG

European journal of obstetrics, gynecology, and reproductive biology1 Jul 2002Cited by 9 (Europe PMC)

PMID12069736DOI10.1016/s0301-2115(01)00297-4PepBankPUB-12069736

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, total hMG dosage was 39.8±14.2 ampoules with nafarelin versus 37.5±16.1 with buserelin, without significant group differences.
In plain wordsTotal stimulation medication use was similar with nafarelin and buserelin in IVF.
Peptide
Nafarelin
Outcome
IncreaseTotal hMG dosage
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean total hMG dosage
39.8 ampoules
nafarelin group
SD of mean total hMG dosage
14.2 ampoules
nafarelin group
mean total hMG dosage
37.5 ampoules
buserelin group
SD of mean total hMG dosage
16.1 ampoules
buserelin group
Source sentences
Summary
mean (+/-S.D.) total dosage of hMG (ampoules) (37.5+/-16.1: Group B, 39.8+/-14.2: Group N versus 41.9+/-12.6: Group L) and mean daily dosage of hMG (ampoules) (3.1: Group B, 2.8: Group N versus 3.0: Group L) seen were not statistically significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973601
02HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, total hMG dosage was 39.8±14.2 ampoules with nafarelin versus 41.9±12.6 with leuprorelin, without significant group differences.
In plain wordsTotal stimulation medication use was similar with nafarelin and leuprorelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseTotal hMG dosage
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean total hMG dosage
39.8 ampoules
nafarelin group
SD of mean total hMG dosage
14.2 ampoules
nafarelin group
mean total hMG dosage
41.9 ampoules
leuprorelin group
SD of mean total hMG dosage
12.6 ampoules
leuprorelin group
Source sentences
Summary
mean (+/-S.D.) total dosage of hMG (ampoules) (37.5+/-16.1: Group B, 39.8+/-14.2: Group N versus 41.9+/-12.6: Group L) and mean daily dosage of hMG (ampoules) (3.1: Group B, 2.8: Group N versus 3.0: Group L) seen were not statistically significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973602
03HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, daily hMG dosage was 2.8 ampoules with nafarelin versus 3.1 with buserelin, without significant group differences.
In plain wordsDaily stimulation medication use was similar with nafarelin and buserelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseDaily hMG dosage
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean daily hMG dosage
2.8 ampoules
nafarelin group
mean daily hMG dosage
3.1 ampoules
buserelin group
Source sentences
Summary
mean daily dosage of hMG (ampoules) (3.1: Group B, 2.8: Group N versus 3.0: Group L) seen were not statistically significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973603
04HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, daily hMG dosage was 2.8 ampoules with nafarelin versus 3.0 with leuprorelin, without significant group differences.
In plain wordsDaily stimulation medication use was similar with nafarelin and leuprorelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseDaily hMG dosage
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean daily hMG dosage
2.8 ampoules
nafarelin group
mean daily hMG dosage
3 ampoules
leuprorelin group
Source sentences
Summary
mean daily dosage of hMG (ampoules) (3.1: Group B, 2.8: Group N versus 3.0: Group L) seen were not statistically significantly different.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973604
05HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, time to the next menstrual period was 9.1±4.1 days with nafarelin versus 10±5.5 with buserelin, without significant group differences.
In plain wordsTime to the next period was similar with nafarelin and buserelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseTime to menstrual period
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean time from starting GnRH analogue to next menstrual period
9.1 days
nafarelin group
SD of mean time from starting GnRH analogue to next menstrual period
4.1 days
nafarelin group
mean time from starting GnRH analogue to next menstrual period
10 days
buserelin group
SD of mean time from starting GnRH analogue to next menstrual period
5.5 days
buserelin group
Source sentences
Summary
The duration between starting the different gonadotrophin-releasing hormone (GnRHa) and the beginning of the next menstrual period was also not seen to be statistically significantly different between the three groups (Group B: 10+/-5.5, Group N: 9.1+/-4.1 versus Group L: 8.2+/-3, days).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973605
06HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, time to the next menstrual period was 9.1±4.1 days with nafarelin versus 8.2±3 with leuprorelin, without significant group differences.
In plain wordsTime to the next period was similar with nafarelin and leuprorelin in IVF.
Peptide
Nafarelin
Outcome
IncreaseTime to menstrual period
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
mean time from starting GnRH analogue to next menstrual period
9.1 days
nafarelin group
SD of mean time from starting GnRH analogue to next menstrual period
4.1 days
nafarelin group
mean time from starting GnRH analogue to next menstrual period
8.2 days
leuprorelin group
SD of mean time from starting GnRH analogue to next menstrual period
3 days
leuprorelin group
Source sentences
Summary
The duration between starting the different gonadotrophin-releasing hormone (GnRHa) and the beginning of the next menstrual period was also not seen to be statistically significantly different between the three groups (Group B: 10+/-5.5, Group N: 9.1+/-4.1 versus Group L: 8.2+/-3, days).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973606
07HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, abandoned cycles occurred in 11.3% with nafarelin versus 11.8% with buserelin, without a significant group difference.
In plain wordsAbandoned cycle rates were similar with nafarelin and buserelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseAbandoned cycles
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
abandoned cycles
11.3%
nafarelin group
abandoned cycles
11.8%
buserelin group
Source sentences
Summary
The number of abandoned cycles was higher in Group L (17% versus 11.8%: Group B and 11.3%: Group N) but this difference did not reach statistical significance.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973607
08HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, abandoned cycles occurred in 11.3% with nafarelin versus 17% with leuprorelin, without a significant group difference.
In plain wordsAbandoned cycle rates were similar with nafarelin and leuprorelin in IVF.
Peptide
Nafarelin
Outcome
DecreaseAbandoned cycles
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
abandoned cycles
11.3%
nafarelin group
abandoned cycles
17%
leuprorelin group
Source sentences
Summary
The number of abandoned cycles was higher in Group L (17% versus 11.8%: Group B and 11.3%: Group N) but this difference did not reach statistical significance.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973608
09HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, pregnancy per retrieval was 12.8% with nafarelin versus 31.1% with buserelin, without significant group differences.
In plain wordsPregnancy rates per retrieval did not differ significantly between nafarelin and buserelin.
Peptide
Nafarelin
Outcome
DecreasePregnancy per oocyte retrieval
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
clinical pregnancy rate per oocyte retrieval
12.8%
nafarelin group
clinical pregnancy rate per oocyte retrieval
31.1%
buserelin group
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973609
10HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, pregnancy per retrieval was 12.8% with nafarelin versus 20.5% with leuprorelin, without significant group differences.
In plain wordsPregnancy rates per retrieval did not differ significantly between nafarelin and leuprorelin.
Peptide
Nafarelin
Outcome
DecreasePregnancy per oocyte retrieval
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
clinical pregnancy rate per oocyte retrieval
12.8%
nafarelin group
clinical pregnancy rate per oocyte retrieval
20.5%
leuprorelin group
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973610
11HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, pregnancy per transfer was 14% with nafarelin versus 35% with buserelin, without significant group differences.
In plain wordsPregnancy rates per transfer did not differ significantly between nafarelin and buserelin.
Peptide
Nafarelin
Outcome
DecreasePregnancy per embryo transfer
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
clinical pregnancy rate per embryo transfer
14%
nafarelin group
clinical pregnancy rate per embryo transfer
35%
buserelin group
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973611
12HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, pregnancy per transfer was 14% with nafarelin versus 23.7% with leuprorelin, without significant group differences.
In plain wordsPregnancy rates per transfer did not differ significantly between nafarelin and leuprorelin.
Peptide
Nafarelin
Outcome
DecreasePregnancy per embryo transfer
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Measurements
clinical pregnancy rate per embryo transfer
14%
nafarelin group
clinical pregnancy rate per embryo transfer
23.7%
leuprorelin group
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973612
13HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, ongoing pregnancy rates did not differ significantly between nafarelin and buserelin.
In plain wordsOngoing pregnancy rates were similar with nafarelin and buserelin.
Peptide
Nafarelin
Outcome
No significant changeOngoing pregnancy
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973613
14HumanNon-randomized trialEfficacy outcome
In women undergoing IVF, ongoing pregnancy rates did not differ significantly between nafarelin and leuprorelin.
In plain wordsOngoing pregnancy rates were similar with nafarelin and leuprorelin.
Peptide
Nafarelin
Outcome
No significant changeOngoing pregnancy
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973614
15HumanNon-randomized trialSafety outcome
In women undergoing IVF, allergic nasal reactions were more frequent with nafarelin than the other groups, including buserelin (P=0.001).
In plain wordsAllergic nasal reactions were more frequent with nafarelin than buserelin in IVF.
Peptide
Nafarelin
Outcome
IncreaseAllergic nasal reactions
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Adverse events · Respiratory
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Apart from a statistically significantly greater incidence of allergic nasal reactions in the nafarelin group (P=0.001), all other side-effects were not shown to be statistically significantly different between the three groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973615
16HumanNon-randomized trialSafety outcome
In women undergoing IVF, allergic nasal reactions were more frequent with nafarelin than the other groups, including leuprorelin (P=0.001).
In plain wordsAllergic nasal reactions were more frequent with nafarelin than leuprorelin in IVF.
Peptide
Nafarelin
Outcome
IncreaseAllergic nasal reactions
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Adverse events · Respiratory
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Apart from a statistically significantly greater incidence of allergic nasal reactions in the nafarelin group (P=0.001), all other side-effects were not shown to be statistically significantly different between the three groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973616
17HumanNon-randomized trialSafety outcome
In women undergoing IVF, other side effects did not differ significantly between nafarelin and buserelin.
In plain wordsOther side effects were similar with nafarelin and buserelin in IVF.
Peptide
Nafarelin
Outcome
No significant changeOther side effects
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Adverse events · Whole body
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Apart from a statistically significantly greater incidence of allergic nasal reactions in the nafarelin group (P=0.001), all other side-effects were not shown to be statistically significantly different between the three groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973617
18HumanNon-randomized trialSafety outcome
In women undergoing IVF, other side effects did not differ significantly between nafarelin and leuprorelin.
In plain wordsOther side effects were similar with nafarelin and leuprorelin in IVF.
Peptide
Nafarelin
Outcome
No significant changeOther side effects
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Adverse events · Whole body
Studied dose
400 microg twice daily · intranasalAs given in this study (human).
Source sentences
Summary
Apart from a statistically significantly greater incidence of allergic nasal reactions in the nafarelin group (P=0.001), all other side-effects were not shown to be statistically significantly different between the three groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF).
Summary · context
Patients were allocated to three groups to receive buserelin 150 microg nasal spray three times daily (Group B), nafarelin nasal spray 400 microg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to comme…
Report a problemFND-1206973618

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.